Clinical Publications	Scientific Publications
December 2023
CML and the WHO: Why? Berman E et al. J Clin Oncol, December 2023 (epub ahead of print)	Precision isolation of circulating leukemia cells in chronic myelogenous leukemia patients using a novel microfluid device and its clinical applications Ouyaung D et al. Cancers(Basel), December 2023 – open access publication
Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with CML Winn AN et al. JAMA Netw Open, December 2023 – open access publication	Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis Wu A et al. Leukemia, December 2023
Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis at initial presentation: a Report from the BCR::ABL1 Pathology Group Rivera D et al. Mod Pathol, December 2023 (epub ahead of print) – open access publication	The SNP rs460089 in the gene promoter of the drug-transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib Machova Polakova K et al. Leukemia, December 2023 (epub ahed of print) – open access publication
Accelerated-phase CML: de novo and transformed Shanmunagathan N and Hughes TP. Hematology Am Soc Hematol Educ Program, December 2023 – open access publication	A review on characterization of BCR-ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes Zenebe B et al. Hematology Review, December 2023 – open access publication
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ≥ 2 tyrosine kinase inhibitors: a systematic literature review Atallah E et al. Ther Adv Hematol, December 2023 – open access publication	C-Myc inhibition intensified the anti-leukemic properties of imatinib in chronic myeloid leukemia cells Zehtabcheh S et al. Mol Biol Rep, December 2023
Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML Working Group) – in French Réa D et al. Bull Cancer, December 2023 (epub ahead of print) – open access publication	The role of CSE1L silencing in the regulation of proliferation and apoptosis via the AMPK/mTor signaling pathway in chronic myeloid leukemia Liu XY et al. Hematology, December 2023 – open access publication
Resistance mutations in CML and how we approach them - Review Soverini S et al. Hematology Am Soc Educ Program, December 2023 – open access publication	Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia Yin L et al. Hematology, December 2023 – open access publication
SOHO State of the art updates and next questions: Chronic myeloid leukemia and pregnancy: Per Aspera ad Astra” - Review Abruzzese E et al. Clin Lymphoma Myeloma Leuk, December 2023 (epub ahead of print)	miR-181a plays a tumor-suppressor role in chronic myeloid leukemia CD34+ cells partially via SERPINE1 Zhang X et al. Cell Mol Life Sci, December 2023 - open access publication
How to improve treatment-remission eligibility in CML? Review Costa A and Breccia M. Br J Haematol, December 2023 (epub ahead of print) – open access publication	Osimertinib covalently binds to CD34 and eliminates progenitor cells Xia L et al. Cancer Res, December 2023 (epub ahead of print)
The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia Liu L et al. Hematology, December 2023 – open access publication	Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells Yang Y et al. Hematology, December 2023 – open access publication
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy, The Surveillance, Epidemiology, and End Results database, 2000-2019 Sasaki K et al. Cancer, December 2023
Sex-specific incidence of hepatitis B virus flares among BCR-ABL tyrosine kinase inhibitor users in Taiwan Wang LY et al. Pharmacoepidemiol Drug Saf, December 2023
Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans Hofmann J et al. Leukemia, December 2023 – open access publication
Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML Kongruang A et al. Hematology, December 2023 – open access publication
An update of the management of advanced phase chronic myeloid leukemia – Review Short NJ et al. Curr Hematol Malig Rep, December 2023
Evaluation of real-world versus clinical trial outcome of tyrosine kinase inhibitor therapy for chronic myeloid leukemic Collins JB et al. J Oncol Pharm Pract, December 2023 (epub ahead of print) – open access publication
Cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia: Clinical relevance, impact on outcome, preventive measures and treatment strategies – Review Iurlo A et al. Curr Treat Options Oncol, December 2023 (epub ahead of print)
Exploration of treatment-free remission in CML, based on molecular monitoring – Review Zhang Z et al. Cancer Med, December 2023 (epub ahead of print) – open access publication
November 2023
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia Cross NCP et al. Leukemia, November 2023 – open access publication	Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation Huuhtanen J et al. Leukemia, November 2023 (epub ahead of print) – open access publication
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO Study Zambrotta GPM et al. Am J Hematol, November 2023 – open access publication	Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia Shin JE et al. Mol Cancer, November 2023 – open access publication
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: Results from the phase 4 BYOND study Rosti G et al. Leukemia, November 2023 (epub ahead of print) – open access publication	Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment Häselbarth L et al. BMC Cancer, November 2023 – open access publication
Survival with chronic myeloid leukemia after failing milestones Lauseker M et al. Leukemia, November 2023 – open access publication
What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia? Kantarjian HM Leukemia, November 2023
The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib and ponatinib Mulas O et al. Ann Hematol, November 2023
Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor Park H et al. Ther Adv Hematol, November 2023 – open access publication
Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients Rafiq Mohammed A et al. Gene, November 2023
October 2023
Viral infections and incidence of reactivation in chronic myeloid leukemia patients – Review Aldapt MB et al. Oncology, October 2023 (epub ahead of print)	Transporter-mediated cellular distribution of tyrosine kinase inhibitors as a potential resistance mechanism in chronic myeloid leukemia - Review Verhagen NE et al. Pharmaceutics, October 2023 – open access publication
Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network analysis – Review Zhang S et al. Expert Opin Drug Saf, October 2023 (epub ahead of print)	Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia Han H et al. Biochem Pharmacol, October 2023 (epub ahead of print)
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions Larfors G et al. Eur J Haematol, October 2023 – open access publication	A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells Zhang X et al. Cell Mol Biol Lett, October 2023 – open access publication
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy Khadadah FM et al. Leuk Res, October 2023	AZD-7648, a DNA-PK inhibitor, induces DNA damage, apoptosis, and cell cycle arrest in chronic and acute myeloid leukemia cells Lapa BS et al. Int J Mol, October 2023 – open access publication
Revisiting six established practices in the treatment of chronic myeloid leukemia - Review Kantarjian HM et al. Lancet Haematol, October 2023	Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis Boucher L et al. Int J Mol, October 2023 – open access publication
Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results Gener-Ricos C et al. Clin Lymphoma Myeloma Leuk, October 2023
Spontaneous remission in a patient with chronic myeloid leukemia: A Case Report Alshurufa A et al. Case Rep Oncol, October 2023 – open access publication
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia Efficace F et al. Cancer, October 2023 (epub ahead of print)
September 2023
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib Kok CH et al. Blood Cancer J, Sept 2023 (epub ahead of print) – open access publication	Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention Shanmunagathan N et al. Haematologica, Sept 2023 – open access publication
Survival with chronic myeloid leukemia after failing milestones Lauseker M et al. Leukemia, September 2023 (epub ahead of print) – open access publication	New patterns of genetic instability in chronic myeloid leukemia: Interesting, but not ready for clinical use Schiffer CA. Haematologica, Sept 2023 – open access publication
Treatment-free remission after dasatinib in patients with chronic myeloid leukemia in chronic-phase with deep molecular response: Final 5-year analysis of DASFREE Shah NP et al. Br J Haematol, Sept 2023 - open access publication	Aquired miR-142 deficit in leukemia stem cells suffices to drive chronic myeloid leukemia into blast crisis Zhang B et al. Nat Commun, Sept 2023 – open access publication
The (near) miracle of therapy in chronic myeloid leukemia Radich JP. Br J Haematol, Sept 2023 – open access publication	Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells Okabe S and Gotoh A. BMC Cancer, Sept 2023
Improvement, implementation, and evaluation of the CMyLife Digital Care Platform: Participatory Action Research Approach Verweij L et al. J Med Internet Res, Sept 2023 - open access publication	The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on TKI therapy predicts the imatinib treatment failure Ratajczak B et al. Leuk Res, Sept 2023 – open access publication
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population Kockerols C et al. Eur J Haematol, Sept 2023 (epub ahead of print)	MicroRNA based combinatorial therapy against TKIs resistant CML by inactivating the PI3K/Akt/mTOR pathway: a review Sing P. Med Oncol, Sept 2023
External validation of the predictive scoring systems for molecular responses in chronic myeloid leukemia receiving initial imatinib therapy Qi F et al. Leukemia, Sept 2023
Final report of TKI discontinuation trial with dasatinib for the second attempts of treatment-free remission after failing the first attempts with imatinb: Treatment-free Remission Accomplished by Dasatinib (TRAD) Study Perusini MA et al. Br J Haematol, Sept 2023 (epub ahead of print)
Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukemia Del Rosario García B et al. J Oncol Pharm Pract, Sept 2023 (epub ahead of print)
The expanding CML treatment landscape: an introspective commentary Lipton JH, Blood Cancer J, Sept 2023 (epub ahead of print) – open access publication
Bilateral massive retinal infiltrates: Sign of blast crisis in chronic myeloid leukemia Patel A et al. Ophthalmology, Sept 2023 (epub ahead of print)
Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice Ielo C et al. Leuk Lymphoma, Sept 2023 (epub ahead of print)
Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase Oyogoa E et al. Front Oncol, Sept 2023 – open access publication
August 2023
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies Bhattacharjee U et al. Leuk Res, August 2023 (epub ahead of print)	Using natural killer cell-derived exosomes as a cell-free therapy for leukemia Samara A et al. Hematol Oncol, August 2023
One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission Laganà A et al. Eur J Haematol, August 2023 (epub ahead of print)	NDRG3 regulates imatinib resistance by promoting ß-catenin accumulation in the nucleus in chronic myelogenous leukemia Wang X et al. Oncol Rep, August 2023 – open access publication
Association of nilotinib with cardiovascular diseases in patients with chronic myelogenous leukemia: A National PopulationBased Cohort Study Huang CE et al. Oncologist, August 2023 (epub ahead of print) – open access publication	Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia Martínez-Castillo M et al. Leuk Res, August 2023
Measuring chronic myeloid leukemia TKI-related toxic effects in the real-world: a systematic review and critical assessment of content validity of patient-reported outcomes measures - Review Smit Y et al. Lancet Haematol, August 2023 (epub ahead of print)	Mitochondrial dysfunction in cardiotoxicity induced by BCR-ABL1 tyrosine kinase inhibitors – underlying mechanisms, detection, potential therapies – Review Sun S et al. Cardiovasc Toxicol, August 2023
Real-world experience with ponatinib therapy in chronic-phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events Abdelmagid MG et al. Blood Cancer J, August 2023 (epub ahead of print) – open access publication	Crizotinib acts as a ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL T315I and BCR-ABL1 T315I-E255KMian AA et al. Ann Hematol, August 2023 – open access publication
Reverse transcription can critically impact the diagnostic outcome of BCR::ABL1 quantitative real-time RT-PCR Spiess B et al. Cancers(Basel) – open access publication	MEK1/2 regulates normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia Mazzera L et al. Leukemia, August 2023 – open access publication
Interferon in chronic myeloid leukemia: Is it useful for treatment-free remission? Breccia M and Saglio G. Br J Haematol, August 2023 (epub ahead of print) – open access publication	High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors Aghel N et al. Leuk Lymphoma, August 2023 (epub ahead of print)
Step-in dosing of bosutinib in patients with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study Isfort S et al. Ann Hematol, August 2023 (epub ahead of print) – open access publication	Food for thought (and CML survival) Sezaki M and Huang G. Blood, August 2023
Population modelling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia Garret M et al. Cancer Med, August 2023 (epub ahead of print) – open access publication	Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells Rattigan KM et al. Nat Commun, August 2023 – open access publication
Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy Pagani IS et al. Blood, August 2023 (epub ahead of print)	The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associations with each resistance mechanisms Leow BCS et al. Sci Rep, Aug 2023 – open access publication
July 2023
Immune modulation in chronic myeloid leukemia patients treated with nilotinib and interferon-alpha Irani YD et al. Br J Haematol, July 2023 (epub ahead of print)	Genetic separation of chronic myeloid leukemia stem cells from normal hematopietic stem cells at single-cell resolution Chen Y et al. Leukemia, July 2023 – open access publication
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study Cortes JE et al. Haematologica, July 2023 (epub ahead of print) – open access publication	Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukemia stem cells Rattigan KM et al. EMBO Rep, July 2023 (epub ahead of print) – open access publication
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia Balsat M et al. Leuk Res, July 2023	Profiling of miRNAs and their interfering targets in peripheral blood mononuclear from patients with chronic myeloid leukemia Wu SC et al. Front Oncol, July 2023 – open access publication
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia Huguet F et al. Expert Rev Hematol, July 2023 (epub ahead of print)	Control of PH+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors Ansari S and Verma M. Med Oncol, July 2023
Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia Chen Y et al. Cancer Med, July 2023 (epub ahead of print) – open access publication	HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway Yin L et al. Hum Cell, July 2023
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era Haddad FG et al. Am J Hematol, July 2023 (epub ahead of print)	Phenotypic and functional characterization of subpopulation of imatinib resistant chronic myeloid leukemia cell line Hekmatshoar Y et al. Adv Med Sci, July 2023 (epub ahead of print)
Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia Braga AGO et al. Hematol Transfus Cell Ther, July 2023 (epub ahead of print) – open access publication	Histone demethylase PHF8 facilitates the development of chronic myeloid leukemia by directly targeting BCR::ABL1 Feng H et al. Br J Haematol, July 2023 (epub ahead of print) – open access publication
Real-world management of CML: outcomes and treatment patterns Held N and Atallah EL. Curr Hematol Malig Rep, July 2023 (epub ahead of print)
Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients Jacobi H et al. Front Pharmacol, July 2023 – open access publication
Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient Nohoglu Kantarci E et al. Cancer, July 2023 (epub ahead of print)
June 2023
Impact of tyrosine kinase inhibitors applied for first-line chronic myeloid leukemia treatment on platelet function in whole blood of healthy volunteers in vitro Eckart F et al. Hamostaseologie, June 2023 – open access publication	Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis Radich JP et al. Haematologica, June 2023 – open access publication
Single cells tell multiple tales in CML Ross DM. Blood, June 2023 – open access publication	Project Confirm: Accelerated drug approvals for chronic myeloid leukemia Sweet KL et al. Clin Cancer Res, June 2023
Association of pre-treatment bone marrow morphology and achievement of BCR-ABL1 transcript milestone in CML Murkoviç M et al. Pathol Res Pract, June 2023	Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML Tribelli M et al. Cancer, June 2023 (epub ahead of print) – open access publication
BCR-ABL promotes hematopoietic stem and progenitor cell formation in embryonic stem cells Artus J et al. Exp Hematol, June 2023 (epub ahead of print)	Management of chronic myeloid leukemia patients in later lines: The role of ponatinib and new compounds - Review Scalzulli E et al. Clin Lymphoma Myeloma Leuk, June 2023
Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia – Review Am Soc Clin Oncol Educ Book, June 2023 – open access publication	Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress Kantarjian HM and Tefferi A. Am J Hematol, June 2023 (epub ahead of print) – open access publication
Chronic myeloid leukemia during pregnancy with placental involvement: Case Report and Literature Review Çobankent Aytekin E et al. Fetal Pediatr Pathol, June 2023	Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey Chen H et al. Leuk Lymphoma, June 2023 (epub ahead of print)
	Switching from imatinib to nilotinib plus pegylated interferon α2b in chronic phase chronic myeloid leukemia failing to achieve deep molecular response: clinical and immunologica effects Geelen IGP et al. Ann Hematol, June 2023
	Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulation surviving Yin SS et al. Cell Cycle, June 2023 – open access publication
	Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukemia cells Tsubaki M et al. Cell Prolif, June 2023 – open access publication
May 2023
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery? Padala S and Cortes J. Haematologica, April 2023 (epub ahead of print) – open access publication	Modulating retinoid-x-receptor alpha RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo Rajmani BM et al. Front Pharmacol, May 2023 - open access publication
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal Pavlovsky C et al. J Hematol Oncol, April 2023 – open access publication	Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model Langhammer M et al. Leukemia, May 2023 (epub ahead of print) – open access publication
Cardiovascular risk in chronic myeloid leukemia: A multidisplinary consensus on screening and management Milojkovic D et al. Eur J Haematol, April 2023 (epub ahead of print) – open access publication	Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells Hiroshi H et al. Sci Rep, May 2023 – open access publication
Gene expression pattern of ESPL1, PTTG1 and PTTG1IP can potentially predict response to TKI first-line treatment of patients newly diagnosed CML Christiani E et al. Cancers(Basel), May 2023 – open access publication	Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells Qiu S et al. Blood, May 2023 (epub ahead of print)
A pragmatic approach to managing long-term adverse effects in chronic myeloid leukemia treatment - Review Lucero JA and Lipton JH. Curr Hematol Malig Rep, May 2023 (epub ahead of print)	Frequency and driver mutation diversity in concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm Langabeer SE et al. Int J Hematol, April 2023 (epub ahead of print)
The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist - Review Clements J et al. Future Oncol, May 2023 (epub ahead of print) – open access publication	Differentiation of imatinib-resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A. Xu Y et al. Cancer, May 2023 – open access publication
SOHO state of the art updates and next questions / Update on treatment-free-remission in chronic myeloid leukemia (CML) - Review Mikhaeel S and Atallah E. Clin Lymphoma Myeloma Leuk, May 2023	I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition Gao C et al. Front Pharmacol, April 2023 – open access publication
Imatinib compared to second-generation tyrosine kinase inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase Yang S et al. Am J Hematol, May 2023 (epub ahead of print) – open access publication	Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells Mitrovsky O et al. PLoSOne, May 2023 – open access publication
Response-based dosing for ponatinib: Model-based analyses of the dose-ranging OPTIC study Hanley MJ et al. Clin Pharmacol Ther, May 2023 (epub ahead of print)	Modeling global genomic instability in chronic myeloid leukemia (CML) using patient-derived induced pluripotent stem cells (iPSCs) Telliam G et al. Cancers(Basel), May 2023 – open access publication
Chronic Myeloid Leukemia following Exposure to Radioactive Iodine (I131): A Systematic Review Ali Hailan YM et al. Oncology, May 2023 – open access publication
A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia Kaddoura R et al. Front Med, May 2023 – open access publication
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplant - Review Uhm J. Blood Res, April 2023 - open access publication
Developing therapeutic approaches for CML: a review Kumar V et al. Mol Cell Biochem, May 2023
The EMA assessment of Asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who were previously treated with at least two tyrosine kinase inhibitors Tesileanu CMS et al. Oncologist, May 2023 (epub ahead of print) – open access publication
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase focusing on age and dose effects Tokuhira M et al. Int J Hematol, May 2023 (epub ahead of print)
Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted! Eskazan AE et al. Cancer, May 2023 (epub ahead of print)
JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response Tossoni L et al. Ann Hematol, May 2023
April 2023
The outcome of post-transplant asciminib in patients with CML Fernando F et al. Bone Marrow Transplant, April 2023 (epub ahead of print)	New patterns of genetic instability in chronic myelogenous leukemia: interesting, but not ready for clinical use Schiffer CA. Haematologica, April 2023 (epub ahead of print) – open access publion
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial Réa D et al. Leukemia, April 2023 (epub ahead of print) – open access publication	The structure of the hematopoietic system can explain chronic myeloid leukemia progression Pérez-Jiménez M et al. Sci Rep, April 2023 – open access publication
Management of chronic myeloid leukemia in 2023 – Common ground and common sense - Review Senapati J et al. Blood Cancer J, April 2023 – open access publication	Characterization of bone marrow niche in chronic myeloid leukemia patients identifies CXCL14 as a new therapeutic option Polinska M et al. Blood, April 2023 (epub ahead of print)
Efficacy and safety of nilotinib in chronic myeloid leukemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study Dulucq S et al. Br J Haematol, April 2023 (epub ahead of print) – open access publication	IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia Fiordi B et al. Haematologica, April 2023 (epub ahead of print) – open access publication
Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event Tarantini F et al. Leuk Res, April 2023	Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia Zhong FM et al. Cancer Cell Int, April 2023 – open access publication
Managing women of childbearing age with chronic myeloid leukemia: Safety and treatment considerations Expert Rev Hematol, April 2023 (epub ahead of print)	Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia Zhong FM et al. Cancer Cell Int, April 2023 – open access publication
An analysis of dasatinib treatment patterns in patients with chronic myeloid leukemia after experiencing pleural effusion during dasatinib therapy McBride A et al. Acta Haematol, April 2023 (epub ahead of print)
Efficacy and safety of nilotinib as frontline therapy in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials Luciano L et al. Ann Hematol, April 2023 (epub ahead of print) – open access publication
Applications of machine learning in chronic myeloid leukemia - Review Elhadary M et al. Diagnostics(Basel), April 2023 – open access publication
Breaking the mold: asciminib as a standard of care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting Yilmaz R et al. Future Oncol, April 2023 (epub ahead of print)
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia – Review Han JJ et al. Blood Res, April 2023 (epub ahead of print) – open access publication
Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings - Review Cheng F et al. Front Oncol, April 2023 – open access publication
Assessment of imatinib as a primary treatment of chronic myeloid leukemia in chronic phase: a Cohort Study Merin D et al. J Oncol Pharm Pract, April 2023
March 2023
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Hochhaus A et al. Leukemia, March 2023 – open access publication	AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells Lee YC et al. Biochem Pharmacol, March 2023
A sciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results Mauro MJ et al. Leukemia, March 2023 (epub ahead of print) – open access publication	The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere lengths in chronic myeloid leukemia Deregowska A et al. J Cancer Res Clin Oncol, March 2023 (epub ahead of print) – open access publication
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention Shanmunagathan N et al. Haematologica, March 2023 (epub ahead of print) – open access publication	Induction of DNMT1-dependent demethylation of SHP-1 by the natural flavonoid compound Baicalein overcame imatinib-resistance in CML CD34+ cells Xu X et al. Cell Commun Signal, March 2023 – open access publication
Editorial: Advances in the treatment of chronic myeloid leukemia Eskazan AE et al. Front Oncol, March 2023 – open access publication	Imatinib blocks tyrosine phosphorylation of Smad4 and restores TFG-ß growth-suppressive signaling in BCR-ABL1-positive leukemia Wang L et al. Signal Transduct Target Ther, March 2023 – open access publication
High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population Kockerols CCB et al. Haematologica, March 2023 (epub ahead of print) – open access publication	The prognostic and therapeutic potential of HO-1 in leukemia and MDS – Review Sadeghi M et al. Cell Commun Signal, March 2023 – open access publication
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence Shallis RM et al. Blood Adv, March 2023 (epub ahead of print) – open access publication	NOX2 and NOX4 control mitochondrial function in chronic myeloid leukemia Romo-González M et al. Free Radic Biol Med, March 2023 – open access publication
The economic burden of chronic myeloid leukemia in patients with later lines: Findings from a real-world analysis in Italy Breccia M et al. Adv Ther, March 2023 – open access publication	TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN Qiu Q et al. Signal Transduct Target Ther, March 2023 – open access publication
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia Krishnan V et al. Blood, March 2023 (epub ahead of print)	Molecular mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia Kaehler M and Cascorti I. Handb Exp Pharmacol, March 2023 (epub ahead of print)
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian Medicines Agency (AIFA) Breccia M et al. Ann Hematol, March 2023 (epub ahead of print)
Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm Walia A and Prasad V. Blood Cancer J, March 2023 – open access publication
Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia Aleem A et al. Int J Hematol, March 2023 (epub ahead of print)
Association between bariatric surgery and outcomes in chronic myeloid leukemia Haddad FG et al. Cancer, March 2023 (epub ahead of print)
Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase – Review Choi EJ. Blood Res, March 2023 (epub ahead of print) – open access publication
Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia (RODEO study): study protocol for prospective, multicentre, single-arm trial Djodikromo MF et a. BMC Cancer, March 2023 – open access publication
February 2023
Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells Tsubaki M et al. BMB Rep, February 2023 – open access publication	Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for the novo lymphoid blast phase-chronic myeloid leukemia Yang Z et al. Leuk Res, February 2023 (epub ahead of print)
Repurposing the Bis-Biguanide Alexidine in combination with tyrosine kinase inhibitors to eliminate leukemic stem/progenitor cells in chronic myeloid leukemia Muselli F et al. Cancers(Basel), February 2023 – open access publication	Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: characteristics, potential mechanism, and clinical management strategies – Review Cheng F et al. Front Oncol, February 2023 – open access publication
Discovery of CZS-241: A potent, selective, and orally available Polo-like kinase 4 inhibitor for the treatment of CML Sun Y et al. J Med Chem, February 2023	Cardiovascular toxicities associated with tyrosine kinase inhibitors - Review Sahegh N et al. Curr Cardiol Rep, February 2023 (epub ahead of print)
Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia Jiang B et al. Front Oncol, February 2023 – open access publication	The bone marrow immune environment in CML: Treatment responses, treatment-free remission and therapeutic vulnerabilities Patterson SD & Copland M. Curr Hematol Malig Rep, February 2023 (epub ahead of print) – open access publication
A survey of patient experience in CML: American and Canadian Perspectives Hillis C et al. Patient Prefer Adherence, February 2023 – open access publication
Importance of tyrosine kinase inhibitor treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-Free study Yoshida C et al. Int J Hematol, February 2023 (epub ahead of print) – open access publication
Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network Nunes RAB et al. Front Cardiovasc Med, February 2023 – open access publication
Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison Hyland KA et al. Leuk Lymphoma, February 2023
Family planning and pregnancy in patients with chronic myeloid leukemia – Review Berman E et al. Curr Hematol Malig Rep, February 2023 (epub ahead of print)
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modelling and pathway analysis Radich JP et al. Haematologica, February 2023 (epub ahead of print) – open access publication
January 2023
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in CML Irani YD et al. Blood Adv, January 2023 (epub ahead of print) – open access publication	Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Hochhaus A et a. Leukemia, January 2023 (epub ahead of print) – open access publication
RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia Zhang H et al. Haematologica, January 2023 – open access publication	Matching adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors Atallah E et al. J Caner Res Clin Oncol, January 2023 (epub ahead of print) – open access publication
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib Häselbarth L et al. Cancer Immunol Immunother, January 2023 (epub ahead of print) – open access publication	Allogeneic transplantation for chronic myeloid leukemia: I’m not dead yet! Radich J. Am J Hematol, January 2023 – open access publication
mTORC2 is activated under hypoxia and could support chronic myeloid leukemia stem cells Panuzzo C et al. Int J Mol Sci, January 2023 – open access publication	Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor Bidikian A et al. Am J Hematol (epub ahead of print)
BH3 mimetics and TKI combined therapy for CML Brumatti G et al. Biochem, January 2023 – open access publication	The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors Jabbour EJ et al. Am J Hematol, January 2023 (epub ahead of print)
Differential inhibition of T cell receptor and STAT5 signalling pathways determine the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia Harrington P et al. Haematologica, January 2023 (epub ahead of print) – open access publication	A systematic review on second treatment-free remission (TFR) attempt in chronic myeloid leukemia (CML): Can it be applied in clinical practice? - Review Çiftçiler R et al. Clin Lymphoma Myeloma Leuk (epub ahead of print)
	Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring Bataller A et al. Leuk Lymphoma, January 2023 (epub ahead of print)
	Is it time to reconsider molecular response milestones in CML? Walia A and Prasad V. Am J Hematol, January 2023 (epub ahead of print)

Professor of Medicine
Associate Cancer Service Line Director

Division of Hematology & Oncology
Medical College of Wisconsin
Milwaukee, Wisconsin (USA)

Ehab Atallah is a Professor of Medicine at the Medical College of Wisconsin Division of Hematology and Oncology, specialising in leukemia, myelodysplastic syndromes, myeloproliferative neoplasms and other bone marrow failure disorders in Froedtert Hospital in Milwaukee (USA).

He graduated from Cairo University School of Medicine and completed an internal medicine residency in the Cleveland Clinic Health System and a fellowship in hematology/oncology at the Karmanos Cancer Center in Detroit, Michigan, where he also served as Chief Fellow. Following this, he completed a leukemia fellowship at M.D. Anderson Cancer Center in Houston, Texas.

Dr Atallah’s current research interests are treatment of patients with CML, AML, CLL, ALL, myeloproliferative neoplasms and myelodysplastic syndromes. He is also the administrative director of the H Jean Khoury Cure CML Consortium (HJKC3). The HJKC3 is a collaborative effort of physicians and researchers at 21 academic medical centers committed to CML research and improving patient care and quality of life.

Clinical Publications	Scientific Publications
December 2022
Project Confirm: Accelerated drug approvals for chronic myeloid leukemia Sweet KL et al. Clin Cancer Res, December 2022 (epub ahead of print)
Management of TKI-resistant chronic phase CML - Review Hughes TP and Shanmunagathan N. Hematology Am Soc Hematol Educ Program, December 2022	Genetic landscape of chronic myeloid leukemia - Review Ochi Y. Int J Hematol, December 2022 (epub ahead of print)
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic-phase: the ASC4FIRST phase III trial Cortes JE et al. Future Oncol, December 2022 (epub ahead of print) - open access publication	Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition Bütow M et al. Haematologica, December 2022 (epub ahead of print) – open access publication
Treatment of CML in pregnancy Robertson HF and Apperley JF. Hematology Am Soc Hematol Educ Program, December 2022	Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation Karg E et al. Front Oncol, December 2022 – open access publication
Measurable residual disease in leukemia - Review Branford S and Apperley JF. Haematologica, December 2022 – open access publication	Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukemia (CML) by disrupting glycerophospholipid metabolism Gonzalez MA et al. Clin Transl Med, December 2022 – open access publication
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM1 trial Dulucq S et al. Haematologica, December 2022 – open access publication	JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander? Tarantini F et al. Hematology, December 2022
Chronic myeloid leukemia: the cutting-edge evidence and things we should know Iriyama N et al. Int J Hematol, December 2022 (epub ahead of print)	Wee 1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-yH2AX-MDC1 Zeng F et al. Cell Commun Signal, December 2022 – open access publication
De novo lymphoid blast phase chronic myeloid leukemia: report and contemporary discussion Hameed M et al. Hematology, December 2022 – open access publication	Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicated chronic myeloid leukemia cells Dudka W et al. BMC Cancer, December 2022 – open access publication
Current management of chronic myeloid leukemia myeloid blast crisis - Review Yohanan B and George B. Clin Med Insights Oncol, December 2022 (epub ahead of print)	Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells Zhang J et al. Hematology, December 2022
A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia - Review Ahmed K et al. Front Med (Lausanne), December 2022 – open access publication	Aberrant DNA methylation status and mRNA expression level of SMG1 gene in chronic myeloid leukemia: A case-control study Hojjatipour T et al. Cell J, December 2022
A review of the therapeutic role of the new third-generation TKI Olverembatinib in chronic myeloid leukemia - Review Qian H et al. Front Oncol, December 2022 - open access publication	Correlation of the transcription factors IRF4 and BACH2 with the abnormal NFATC1 expression in T cells from chronic myeloid leukemia patients Zhang Y et al. Hematology, December 2022
Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study Ono T et al. Int J Hematol, December 2022 – open access publication	FUBP3 regulates chronic myeloid leukemia progression through PRC2 complex regulated PAK1-ERK signalling Sharma M et al. J Cell Mol Med, December 2022 (epub ahead of print) – open access publication
Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia Ureshino H et al. Hematology, December 2022 – open access publication	Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor Liu H et al. Eur J Med Chem, December 2022
Transplantation in CML in the TKI era: who, when, and how? Niederwieser C and Kröger N. Hematology Am Soc Hematol Edu Program, December 2022	miR-495-3p sensitizes BCR-ABL1 expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance1 gene in T315I mutated cells Rittavee Y et al. Exp Hematol, December 2022 (epub ahead of print)
	Dvl proteins regulate SMAD1, AHR, mTOR, BRD7 protein expression while differentially regulating canonical and non-canonical Wnt signaling pathways in CML cell lines Caliskan C et al. Gene, December 2022 (epub ahead of print)
November 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia Flynn KE et al. Haematologica, November 2022 – open access publication	BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia Parry N et al. Cell Death Discov, November 2022 – open access publication
Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands Ector GICG et al. Leuk Lymphoma, November 2022 (epub ahead of print)	Integrating single-cell transcriptome and network analysis to characterize the therapeutic response of chronic myeloid leukemia Ma J et al. Int J Mol Sci, November 2022 – open access publication
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis Jabbour E et al. Am J Hematol, November 2022	Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia Knight A et al. Cancer Immunol Immunother, November 2022 (epub ahead of print) – open access publication
Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotonib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis - Review Li S et al. Front Cardiovas Med, November 2022 - open access publication	Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia Ma D et al. Oncogene, November 2022 (epub ahead of print)
Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with chronic myeloid leukemia Ono T et al. Cancer Sci, November 2022 (epub ahead of print) – open access publication	Low c-Kit expression identifies primitive therapy-resistant CML stem cells Shah M et al. JCI Insight, November 2022 (epub ahead of print) – open access publication
Olverembatinib in chronic myeloid leukemia Öziskender R et al. Drugs Today (Barc), November 2022	Hematopoietic and chronic myeloid leukemia stem cells: Multi-stability versus lineage restriction - Review Brown G. Int J Mol Sci, November 2022 – open access publication
The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation Xu Z et al. Leuk Lymphoma, November 2022	SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia Wu DL eta l. Eur J Med Res, November 2022 – open access publication
Extramedullary T-lymphoblastic blast crisis in chronic myeloid leukemia: A very rare case associated with comutation of ABL1 T315I and H396R Zhang Y et al. Int J Lab Hematol, November 2022 (epub ahead of print)	Reciprocal interactions among CobII1, PACSIN2, and SH3BP1 regulate drug resistance in CML Park K et al. Cancer Med, November 2022 – open access publication
A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast crisis and was successfully treated with asciminib Tomassetti S et al. Clin Case Rep, November 2022 – open access publication	Low c-Kit expression identifies primitive therapy-resistant CML stem cells Shah M et al. JCI Insight, November 2022 (epub ahead of print) – open access publication
October 2022
Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party in the EBMT Chalandon Y et al. Am J Hematol, Oct 2022 (epub ahead of print) – open access publication	Secondary fusion proteins as a mechanism of BCR::ABL1 kinase independent resistance in chronic myeloid leukemia Barnes EJ et al. Br J Haematol, Oct 2022 (epub ahead of print)
Dasatinib plus Peg-interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukemia: Results of a multicenter phase 2 study (DASA-Peg IFN Study) Roy L et al. Br J Haematol, Oct 2022 (epub ahead of print)	Prognostic impact of ASXL1 mutations in chronic phase CML Bidikian A et al. Blood Cancer J, Oct 2022 – open access publication
B-lymphoid blast phase chronic myeloid leukemia: Current Therapeutics Yohannan B and George B. Int J Mol Sci, Oct 2022 – open access publication	Non-coding RNAs are implicit in chronic myeloid leukemia therapy-resistance - Review Rudich A et al. Int J Mol Sci, Oct 2022 – open access publication
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency Hochmann MJ et al. Int J Hematol, Oct 2022 (epub ahead of print)	ACSL1 promotes imatinib-induced chronic myeloid leukemia cell senescene by regulating SIRT1/p53/p21 pathway Liu W et al. Sci Rep, Oct 2022 – open access publication
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency Hochmann MJ et al. Int J Hematol, Oct 2022 (epub ahead of print)	Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia Su YL et al. Cancer Sci, Oct 2022 – open access publication
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia - Review Senapati J et al. Leukemia, Oct 2022 (epub ahead of print)	IRF4 Gene expression on the trail of molecular response: looking at chronic myeloid leukemia from another perspective Tarantini F et al. Acta Haematol, Oct 2022 (epub ahead of print)
Real-world therapeutic response and tyrosine kinase discontinuation in chronic-phase chronic myeloid leukemia: data from the French Observatory Saugues S et al. Ann Hematol, Oct 2022	Histone chaperone ASF1A accelerates chronic myeloid leukemia blast crisis by activating Notch signaling Yiu X et al. Cell Death Dis, Oct 2022 – open access publication
Bosutinib-induced late-onset severe liver injury preceded by eopsinophilia Watanabe N et al. Ann Hematol, Oct 2022
BCR::ABL1 levels at first month after tyrosine kinase inhibitor discontinuation predict subsequent maintenance of treatment-free remission: A study from the “GRUPPO TRIVENETO LMC” Di Giusto S et al. Cancer Med, Oct 2022 (epub ahead of print) – open access publication
Volumetric dried blood micro-sampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia Krützmann ME et a. J Pharm Biomed Anal, Oct 2022 (epub ahead of print)	Co-existence of chronic lymphocytic leukemia and chronic myeloid leukemia and underlying pathogenetic mechanisms Badal S et al. Eur J Haematol, Oct 2022 (epub ahead of print)
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care Assanto GM et al. Expert Rev Hematol, Oct 2022 (epub ahead of print)	EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells Vinothkumar K et al. Int J Hematol, Oct 2022 (epub ahead of print)
CML resistant to 2nd generation TKI’s: Mechanisms, next steps, and new directions Scalzulli E et al. Curr Hematol Malig Rep, October 2022 (epub ahead of print)	Molecular changes in chronic myeloid leukemia during tyrosine kinase inhibitors treatment. Focus on immunological pathways Janowski M et al. Onco Targets Ther, Oct 2022 – open access publication
	Association between germline single-nucleotide variants in ADME genes and major molecular response to imatinib in CML patients Estrada N et al. J Clin Med, Oct 2022
September 2022
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia Schönfeld L et al. Leukemia, September 2022 – open access publication	IFN- α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia Huuhtanen J et al. J Clin Invest, September 2022 – open access publication
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring Jabbour E and Kantarjian H. Am J Hematol, September 2022	Targeting the PTP1B-BCR-ABL1 interaction for the degradation of T315I mutant BCR-ABL1 in chronic myeloid leukemia Elgehama A et al. Cancer Sci, September 2022 (epub ahead of print) – open access publication
CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era Vaughn JL et al. Bone Marrow Transplant, September 2022 (epub ahead of print)	Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia Soverini S et al. Leukemia, September 2022
Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population Kockerols CCB et al. Haematologica, September 2022 (epub ahead of print) – open access publication	Ex vivo expansion of phenotypic and transcriptome CML stem cells Patel SB et al. Exp Hematol, September 2022 (epub ahead of print) – open access publication
Deep molecular response in patients with chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TMT614 combined with a tyrosine kinase inhibitor Takahashi N et al. Cancer Med, September 2022 (epub ahead of print) – open access publication	Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance Bührer ED et al. Leukemia, September 2022 (epub ahead of print) – open access publication
Management of chronic myeloid leukemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicine Agency (AIFA) Breccia M et al. Br J Haematol, September 2022 – open access publication	circCRKL, a circ RNA-derived from CRKL, regulates BCR-ABL via sponging miR-877-p5 to promote chronic myeloid leukemia cell proliferation Wang J et al. J Transl Med, September 2022 – open access publication
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities – Review Narli Özdemir Z et al. Int J Hematol, September 2022 (epub ahead of print)	KIF23 promotes autophagy-induced imatinib resistance in chronic myeloid leukemia though activating Wnt/ß-catenin pathway Huang Y et al. Clin Exp Pharmacol Physiol, September 2022 (epub ahead of print) – open access publication
Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia – Review Umezawa Y and Sasaki K. Int J Hematol, September 2022 (epub ahead of print)
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitors? Canon A et al. Leuk Lymphoma, September 2022 (epub ahead of print)
Asciminib vs bosutinib in CML patients pretreated with ≥ 2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL Study Yuda J et al. Cancer Med, September 2022 (epub ahead of print) – open access publication
A unique three-way variant Philadelphia chromosome t(6;9;22) (p21.3;q34;q11.2) in a newly diagnosed patient with chronic myeloid leukemia responded to Flumatinib Chen L et al. Onco Targets Ther, September 2022 – open access publication
August 2022
Defining higher-risk chronic myeloid leukemia: risk scores, genomic landscape, and prognostication – Review Shahrin NH et al. Curr Hematol Malig Rep, August 2022 (epub ahead of print) - open access publication	Reengineering ponatinib to minimize cardiovascular toxicity Hnatiuk AP et al. Cancer Res, August 2022
Onset of blast crisis in chronic myeloid leukemia in treatment-free remission Dulucq S et al. Haematologica, August 2022 (epub ahead of print) – open access publication	Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in TKI-resistant CML cells Kaehler M et al. Oncol Rep, August 2022 – open access publication
Imatinib optimized therapy improves major molecular response rates in patients with chronic myeloid leukemia Johnson-Ansah H et al. Pharmaceutics, August 2022 – open access publication	Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-alderosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia Tsuda M et al. Int J Hematol, August 2022 (epub ahead of print)
Asciminib as a third line option in chronic myeloid leukemia - Review Laganà A et al. Int J Hematol, August 2022 (epub ahead of print)	Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors Hong Y et al. Int Immunopharmacol, August 2022
The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era Kockerols CCB et al. Haematologica, August 2022 – open access publication	Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR:ABL1-independent resistance to tyrosine kinase inhibitors Mancini M et al. Front Oncol, August 2022 – open access publication
Caution in using second generation tyrosine kinase inhibitor, especially for first-line therapy of chronic myeloid leukemia Gambarcorti-Passerini C et al. Am J Hematol, August 2022 – open access publication	Identification of key microRNA as predictive biomarkers of nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial Yen R et al. Leukemia, August 2022 (epub ahead of print)
Real-life analysis and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia Luna A et al. Ann Hematol, August 2022 (epub ahead of print) – open access publication	The mRNA expression of PTEN, LEF1, JAK3, LC3, and p62/SQSTM1 genes in patients with chronic myeloid leukemia Lak ER et a. Cardiovas Hematol Agents Med Chem, August 2022
Olverembatinib (HQP135I), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated CML: results of an open-label, multicenter phase 1/2 trial Jiang Q et al. J Haematol Oncol, August 2022 – open access publication	Activin A downregulates the CD69-MT2A axis via p38 MAPK to induce erythroid differentiation that sensitized BCR-ABL-positive cells to imatinib Chen CW et al. Exp Cell Res, August 2022
TKI dosing for chronic phase CML: the case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day) Tefferi A et al. Am J Hematol, August 2022 (epub ahead of print)
Identification of key microRNA as predictive biomarkers of nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial Yen R et al. Leukemia, August 2022 (epub ahead of print)
Impact of emerging ACA on survival in chronic myeloid leukemia (CML) Hehlmann R et al. Leukemia, August 2022 (epub ahead of print) – open access publication
July 2022
Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors Aslan NA et al. J Oncol Pharma Pract, July 2022 – open access publication	Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA Sánchez R et al. Sci Rep, July 2022 – open access publication
Mechanisms of resistance and implications for treatment strategies in CML - Review Poudel C et al. Cancers(Basel), July 2022 – open access publication	Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia Su YJ et al. Cancer Sci, July 2022 (epub ahead of print) – open access publication
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase - Review García-Gutiérrez V et al. J Hematol Oncol, July 2022 – open access publication	RHOA regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia Zhang H et al. Haematologica, July 2022 (epub ahead of print) – open access publication
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors Haddad FG et al. Am J Hematol, July 2022	Vandetanib drives growth arrest and promotes sensitivity to Imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4 Ma W et al. Mol Oncol, July 2022 – open access publication
Exposure-efficacy analysis of Asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic-phase Combes FP et al. Clin Pharmacol Ther, July 2022 (epub ahead of print)	BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia Peter B et al. Am J Hematol, July 2022 (epub ahead of print)- open access publication
Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor chronic myeloid leukemia patients Lipton NJ and Lipton JH. Leuk Lymphoma, July 2022	Chronic myeloid leukemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype Harrington P et al. Br J Haematol, July 2022 (epub ahead of print) – open access publication
Induction-maintenance for the chronic-phase of chronic myeloid leukemia (IMPACT-I): a prospective, single-arm, phase 2 study Cheung YM et al. Lancet Oncol, July 2022	Allosteric enhancement of the BCR-ABL1 kinase inhibition activity of Nilotinib by co-binding of Asciminib Oruganti B et al. J Biol Chem, July 2022 (epub ahead of print) – open access publication
Co-variates associated with outcomes of tyrosine kinase inhibitor therapy in persons with chronic myeloid leukemia initially presenting in accelerated phase Yang S et al. Leukemia, July 2022	Complex karyotype with double Philadelphia chromosome and T315l mutation results in blastic phase and extensive extramedullary infiltration in a chronic myeloid leukemia patient Davulcu EA et al. Cancer Genet, July 2022 (epub ahead of print)
Migrating to long-read sequencing for clinical routine BCR-ABL1 TKI resistance mutation screening Schaal W et al. Cancer Inform, July 2022 – open access publication	Simultaneous quantification of Dasatinib, Nilotinib, Bosutinib, and Ponatinib using high-performance liquid chromatography-Photodiode array detection Yokoyama Y et al. J Clin Lab Anal, July 2022 (epub ahead of print) – open access publication
Treatment of blast phase chronic myeloid leukemia: A rare and challenging entity – Review Copland M. Br J Haematol, July 2022 (epub ahead of print) – open access publication	Inability to phosphorylate Y88 of P27Kip1 enforces reduced P27 protein levels and accelerated leukemia progression Jäkel H et al. Leukemia, July 2022 – open access publication
Chronic phase CML with sole P190 (e1a2) BCR:ABL1: long-term outcome among ten consecutive cases Abdelmagid MG et al. Blood Cancer J – open access publication
June 2022
Asciminib for chronic myeloid leukemia: Next questions - Review Shanmuganathan N and Hughes TP. Br J Haematol, June 2022 (epub ahead of print)	CRISPR/Cas9-directied gene trap constitutes a selection system for corrected BCR/ABL leukemic cells in CML Vuelta E et al. Int J Mol Sci, June 2022 – open access publication
Initial rate of BCR::ABL1 decline for response prediction in chronic myeloid leukemia Branford S. Turk J Haematol, June 2022 (epub ahead of print) – open access publication	Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML Liu C et al. Cell Metabol, June 2022
French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia (In French) Réa D et al. Bull Cancer, June 2022 (epub ahead of print)	The dawn of allosteric BCR-ABL1 drugs: from a phenotypic screening hit to an approved drug Teng M et al. J Med Chem, June 2022 (epub ahead of print)
Chronic myeloid leukemia: 2022 update on diagnosis, therapy and monitoring Jabbour E and Kantarjian H. Am J Hematol, June 2022 (epub ahead of print)	BCR-ABL1∆E7-8-9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia Tan Y et al. Hematol Oncol, June 2022 (epub ahead of print)
Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy Zhang XS et al. Leukemia, June 2022 (epub ahead of print)	Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy Salmon M et al. Leukemia, June 2022 (epub ahead of print) – open access publication
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukemia at high risk of cardio toxicity Di Lisi D et al. ESC Heart Fail, June 2022 – open access publication	Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission Yu G et a. Leuk Lymphoma, June 2022 (epub ahead of print)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dentritic Neoplasms - Review Khoury JD et al. Leukemia, June 2022 (epub ahead of print) – open access publication	Successful preservation of native BCR::ABL1 in chronic myeloid leukemia primary leukocytes reveals a reduced kinase activity Boni C et al. Front Oncol, June 2022 – open access publication
Future management of chronic myeloid leukemia: From dose optimization to new agents Breccia M et al. Curr Cancer Drug Targets (epub ahead of print)	Modified dentritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation Du Z et al. Exp Hematol Oncol, June 2022 – open access publication
The outcomes of ponatinib therapy in patients with CML resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the Donation Program Sacha T et al. Clin Lymphoma Myeloma, June 2022 – open access publication	Atypical activation of signaling downstream of inactivated BCR-ABL mediates chemoresistance in chronic myeloid leukemia Narasimhan M et al. J Cell Commun Signal, June 2022 (epub ahead of print) – open access publication
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea Ahn SY et al. Blood Res, June 2022 (epub ahead of print) – open access publication	Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia Ozel B et al. Med Oncol, June 2022
Out comes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network Sanz A et al. Blood Cancer J, June 2022 – open access publication
Bosutinib-induced lung injury: a report of two cases and literature review Watanabe N et al. Int J Hematol, June 2022 – open access publication
May 2022
How I treat chronic-phase chronic myelogenous leukemia Berman E. Blood, May 2022	Bioactive lipids as chronic myeloid leukemia’s potential biomarkers for disease progression and response to tyrosine kinase inhibitors de Almeida FC et al. Front Immunol, April 2022 – open access publication
Asciminib: new therapeutic option in chronic-phase CML with treatment-failure Yeung DT et al. Blood, April 2022 (epub ahead of print)	RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia Shanmunagathan N et al. J Mol Diagn, May 2022 (epub ahead of print)
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission Lu L et al. Br J Haematol, May 2022 (epub ahead of print) – open access publication	Novel tyrosine kinase inhibitors to target chronic myeloid leukemia Ciaffaglione V et al. Molecules, May 2022 – open access publication
Chronic myeloid leukemia: a type of MPN Samad MA et al. Blood Res, May 2022 (epub ahead of print) – open access publication	Chromosomal instability in chronic myeloid leukemia: Mechanistic insights and effects Senapati J and Sasaki K. Cancers(Basel), May 2022 – open access publication
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia – What to look for when treatment-free remission is not an option Lipton JH et al. Blood Rev, May 2022 (epub ahead of print) – open access publication	LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients Shehata AMF et al. Leuk Res, May 2022
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial Brümmendorf TH et al. Leukemia, May 2022 (epub ahead of print) – open access publication	Peripheral blood CD26 positive leukemia stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia Ebjan HF et al. Leuk Res Rep, May 2022 – open access publication
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia Flynn KE et al. Haematologica, May 2022 (epub ahead of print) – open access publication
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study White HE et al. Leukemia, May 2022 (epub ahead of print) – open access publication
An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia Yang J et al. Expert Rev Hematol, May 2022 (epub ahead of print)
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM-2 trial Dulucq S et al. Haematologica, May 2022 (epub ahead of print) – open access publication
Lower tumour burden is associated with better cognitive function in patients with chronic-phase chronic myeloid leukemia Li Z et al. Leuk Lymphoma, May 2022 (epub ahead of print)
Long-term outcomes of patients with chronic myeloid leukemia who commenced treatment with imatinib: a 20-year single-centre experience Szczepanek E et al. Leuk Lymphoma, May 2022 (epub ahead of print)
April 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study Gugliotta G et al. Haematologica, April 2022 (epub ahead of print) – open access publication	Overexpression of hepatocyte growth factor protects chronic myeloid leukemia cells from apoptosis induced by etoposide Zheng X et al. Oncol Lett, April 2022 – open access publication
Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: eligibility criteria and predictors of success Inzol E et al. Am J Hematol, April 2022 (epub ahead of print) – open access publication	Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation Adnan Awad S et al. Blood Cancer J, April 2022 – open access publication
Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia Haddad F et al. Leuk Lymphoma, April 2022 (epub ahead of print)	A berrant hyrdroxymethylation in promoter CpG regions of genes related to the cell cycle apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival Guru SA et al. BMC Cancer, April 2022 – open access publication
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation Shimazu Y et al. Hematol Oncol, April 2022 (epub ahead of print)	Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy Li Y et al. Cell Death Discov, April 2022 – open access publication
Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukemia Shivarov V and Grigorova D. Br J Haematol, April 2022 (epub ahead of print) – open access publication
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic leukemia in the United Kingdom and The Netherlands Claudiani S et al. Eur J Haematol, April 2022 (epub ahead of print)
Quantification of atypical BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization? Bhreathnach Ú and Langabeer SE. Int J Lab, April 2022 (epub ahead of print) – open access publication
Aleukemic extramedullary blast crisis as an initial presentation of chronic myeloid leukemia with E1A3 BCR-ABL1 fusion transcript Miyashita N et al. Int Med, April 2022 (epub ahead of print) – open access publication
An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors García-Gutiérrez V and Hernandez-Boluda JC. Expert Rev Hematol, May 2022 (epub ahead of print)
March 2022
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis Takahashi N et al. Int J Hematol, March 2022 (epub ahead of print) – open access publication	Another Philadelphia story Radich J. Haematologica, March 2022 – open access publication
Michele Baccarani, August 16, 1942 to December 20, 2021: a gifted life in hematology Saglio G et al. Bone Marrow Transplant, March 2022 (epub ahead of print) – open access publication	The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients Park H et al. Leuk Res, March 2022
Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: A feasible option also in real-life: A Campus CML study Iurlo A et al. Front Oncol, March 2022 – open access publication	The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia Kumar R et al. Blood Adv, March 2022 (epub ahead of print) – open access publication
Prevalence of anemia among chronic myeloid leukemia patients treated with imatinib: A evidence based meta-analysis Singh AK et al. Curr Rev Clin Exp Pharmacol, March 2022 (epub ahead of print)	Targeting BCR-ABL in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia Roskoski R. Pharmacol Res, March 2022 (epub ahead of print)
Molecular monitoring of BCR-ABL fusion transcripts in patients with chronic myeloid leukemia during treatment using the endpoint fluorescence method Amin H and Ahmed S. Lab Med, March 2022	A kinase inhibitor which specifically targets the ABL myristate pocket (STAM), but unlike asciminib crosses the blood-brain barrier Manley PW et al. Bioorg Med Chem Lett, March 2022
The clinical significance of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive chronic myeloid leukemia who underwent allogeneic hematopoietic cell transplantation Tachibana T et al. Transplant Cell Ther, March 2022 (epub ahead of print)	FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via non-canonical κB-kappa B signaling activation Yang T et al. J Exp Clin Cancer Res, March 2022 – open access publication
Outcomes of pregnancies with chronic myeloid leukemia in the tyrosine kinase inhibitor era and literature review Castillo DL et al. Hematol Rep, March 2022 – open access publication	Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukemia patients during the first year of imatinib therapyExpression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukemia patients during the first year of imatinib therapy Toloza MJ et al. Gene, March 2022
Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentrations in patients with chronic myeloid leukemia receiving first-line nilotinib therapy Fukuda N et al. Cancer Chemother and Pharmacol, March 2022 (epub ahead of print) – open access publication	MiR-199a-3p overexpression suppressed cell proliferation and sensitized chronic myeloid leukemia cells to imatinib by inhibiting mTor signalling Liu X et al. Acta Hematol, March 2022 (epub ahead of print)
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukemia Baccarani M et al. Leukemia, March 2022 (epub ahead of print) – open access publication
Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukemia model Lindström HJG and Friedmann R. Sci Rep, March 2022 – open access publication
February 2022
Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation Shatty D et al. Asia Pac J Clin Oncol, February 2022 – open access publication	TRIB2 regulates the expression of miR-33a-5p through the ERK/c-Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells Sun H et al. Int J Oncol, March 2022 (epub ahead of print) – open access publication
Impact of BCR-ABL1 transcript type on outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A Pairwise and Bayesian Network Meta-Analysis Chen K et al. Front Oncol, February 2022 – open access publication	A systematic review of candidate miRNAs, its targeted genes and pathways in CML – An integrated bioinformatical analysis Elias MH et al. Front Oncol, March 2022 – open access publication
Extramedullary early T-cell lymphoblastic crisis in a young pregnant chronic myeloid leukemia patient: Diagnosis with fine needle aspiration cytology and flow cytometry Murugan R et al. Diagn Cytopathol, Feb 2022 (epub ahead of print)	Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia cells Ianniciello A and Helgasson GV. Autophagy, March 2022 (epub ahead of print)
NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive phase in Taiwan Hwang WL et al. Int J Hematol, February 2022 (epub ahead of print)	Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia Lee KL et al. Leukemia, March 2022 – open access publication
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia Shelton DN et al. PLoS One, March 2022 – open access publication	Commentary on Dominy et al.: Assessment of qualitative PCR for BCR-ABL1 transcripts in CML: Are improved outcomes in patients with e14a2 transcripts an artefact of technology? Branford S. Br J Haematol, February 2022 (epub ahead of print) – open access publication
Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania Robin JB et al. Ann Hematol, March 2022 (epub ahead of print)	Identification of peripheral blood CD26+ leukemia stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia Sharma P et al. Int J lab Hematol, February 2022 (epub ahead of print)
Management of chronic myeloid leukemia and pregnancy: A Bibliometric Analysis (2000-2020) Wang Y et al. Front Oncol, March 2022 – open access publication	Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter frontline TKI’s study (KIARO study) Sicuranza A et al. Front Oncol, February 2022 – open access publication
Transcript and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review Kumar V et al. Mol Cell Biochem, February 2022 (epub ahead of print)	Genomic mechanisms influencing outcome in chronic myeloid leukemia Fernandes A et al. Cancers(Basel), January 2022 – open access publication
Olverembatinib: First Approval Dhillon S et al. Drugs, February 2022 (epub ahead of print)	Discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a review of the biological factors associated with treatment-free remission Stuckey R et al. Curr Oncol Rep, February 2022 (epub ahead of print)
A predictive scoring system for therapy failure in persons with chronic myeloid leukemia receiving initial imatinib therapy Zhang XS et al. Leukemia, February 2022 (epub ahead of print)	Validation and refinement of RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia Lee KL et al. Leukemia, February 2022 (epub ahead of print) – open access publication
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia Pokorny R et al. J Oncol Pharm Pract, February 2022 (epub ahead of print) – open access publication	Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia Kamachi K et al. Cancer Lett, February 2022 – open access publication
	Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia Closa L et al. HLA, February 2022
	Waking up CML leukemia stem cells for the kill Lv K and Tong W. Blood, February 2022 – open access publication
	Identification of peripheral blood CD26+ leukemia stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia Sharma P et al. Int J lab Hematol, February 2022 (epub ahead of print)
	Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter frontline TKI’s study (KIARO study) Sicuranza A et al. Front Oncol, February 2022 – open access publication
	Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia Closa L et al. HLA, February 2022
January 2022
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukemia Gallipoli P et al. Br J Haematol, January 2022 (epub ahead of print) – open access publication	The downregulation of both giant HERCs, HERC1 and HERC2, is an unambiguous feature of chronic myeloid leukemia, and HERC1 levels are associated with leukemia cell differentiation Shahzad Ali M et al. J Clin Med, January 2022 – open access publication
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee Januzzi JL et al. J Hematol Oncol, January 2022 – open access publication	BCR-ABL1 tyrosine kinase complex signalling transduction: challenges to overcome resistance in chronic myeloid leukemia Amarante-Mendes GP et al. Pharmaceutics, January 2022 – open access publication
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002 – 2017 in a complete coverage and nationwide agnostic register study Dahlén T et al. Am J Hematol, January 2022 (epub ahead of print) – open access publication	Imatinib can act as an allosteric activator of ABL kinase Xie T et al. J Mol Biol, January 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1 Réa D and Hughes TP. Crit Rev Oncol Hematol, January 2022 (epub ahead of print) – open access publication	Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors Tanaka Y et al. Nat Commun, January 2022 – open access publication
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology? Dominy KM et al. Br J Haematol, January 2022 (epub ahead of print)	MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis Louati N et al. J Oncol Pharma Pract, January 2022
Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: Who can benefit the most? Efficace F and Baccarani M. J Natl. Cancer Inst, January 2022 – open access publication	Comparative gene expression analysis reveals similarities and differences of chronic myeloid leukemia phases Schwarz A et al. Cancers(Basel), January 2022 – open access publication
The progression of chronic myeloid leukemia to myeloid sarcoma: A systematic review Arzoun H et al. Cureus, January 2022 – open access publication	P-Loop mutations-negative prognosticators in tyrosine kinase inhibitors resistant chronic myeloid leukemia patients Kaleem B et al. Int J Lab Hematol, January 2022 (epub ahead of print)
Asciminib: First Approval Deeks ED et al. Drugs, January 2022 (epub ahead of print)	The prognosis biomarkers based on m6A-related IncRNAs for myeloid leukemia patients Yang LR et al. Cancer Cell Int, January 2022 – open access publication
Late responses in patients with chronic myeloid leukemia initially refractory to tyrosine kinase inhibitors Shaya J et al. Clin Lymphoma Myeloma Leuk, January 2022 – open access publication	Pterostilbene downregulated BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells Kawakami S et al. Sci Rep, January 2022 – open access publication
Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia Kee KM et al. Leuk Res, January 2022	Novel mechanism by a Bis-Pyridinium fullerene derivate to induce apoptosis by enhancing the MEK-ERK pathway in a reactive oxygen species-independent manner in BCR-ABL-positive chronic myeloid leukemia-derived K562 cells Sumi K et al. Int J Mol, January 2022 – open access publication

Mhairi Copland, Professor of Translational Haematology

BSc hons, MBChB, PhD, FRCP, FRCPath

Professor Mhairi Copland initially undertook a medical degree and training in Aberdeen, UK before moving to Glasgow UK to train in haematology. She completed a PhD with Professor Tessa Holyoake at the University of Glasgow on CML stem cells and novel therapies. Professor Copland has remained at the University of Glasgow since and now has a research group studying leukaemia stem cells in AML and CML, as well as novel therapies.

Professor Copland has specific expertise in clinical trials in CML and acute leukaemia, with specific interests in leukameia stem cells, novel therapies in myeloid leukaemias, self-renewal pathways and blast phase CML.

PCea8nY6 400x400

Katia Pagnano MD,PhD

Hematologist and Researcher of the Hematology Division of the Hematology and Hemotherapy Center at the University of Campinas, Campinas, SP, Brazil. (since 1996).

Professor of Medicine, Hematology, at the Pontifical Catholic University of Campinas (since 2021).

Dr Pagnano has previously worked as MD at the Faculty of Medicine-University of Campinas (UNICAMP), Campinas, SP, Brazil. (1991) She did her residency and fellowship training in Hematology, Hemotherapy and Bone Marrow Transplantation at Hospital das Clínicas at UNICAMP (1992-1995) and also undertook a split fellowship at the University of Pennsylvania (Philadelphia,USA) in Dr. Gewirtz lab (1998).

Dr Pagnano has a PhD in Internal Medicine at UNICAMP (2002).

Dr. Pagnano’s expertise is in treating patients with hematologic malignancies, in particular CML, myeloproliferative disorders (MPN) and AML. She has participated in Brazilian CML, AML and MPN guidelines and in the CML Latin America Leukemia Net (LALNET) TFR recommendations. She is a member of the CML Committee from the Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) and the President of the Brazilian CML Working Group.

She has been a member of the iCMLf Advisory Board since 1991 and has previously undertook the iCMLf's iClimb for Cure in 2019 - Kilimanjaro.

Dr Pagnano has participated in several clinical trials, focusing on the treatment of chronic myeloid leukemia, acute myeloid leukemia and lymphomas. She has published in peer-reviewed journals.

maxresdefault

A Heartfelt Thank You: Celebrating the Generosity of our Climb for a Cure - Annapurna Donors

iCMLf Content 2023

The iCMLf Climb for a Cure - Annapurna fundraising adventure is getting closer, and we are incredibly grateful for the support we have received from donors around the world. The funds raised through this initiative will make a lasting impact on the lives of individuals living with Chronic Myeloid Leukemia (CML). We extend our heartfelt thanks to all those who have contributed to this cause so far.

Your generosity enables us to continue the vital work of the iCMLf in advancing research, facilitating optimal management practices for CML globally, and supporting patients and their families. Your donations are an investment in the lives of individuals affected by CML, and they bring hope and renewed strength to those facing this challenging journey.

Donate to the Climb For a Cure Annapurna 2023

Meet the iCMLf Climb For a Cure Acknowledged Partners

Support our climbers and CML Patients 2

Support our climbers and CML Patients

Corporate sponsorship packages are available: pdf Click here (1.21 MB) to download the PDF, or contact Nicola at Nicola.evans@cml-foundation.org for more information.

Meet the iCMLf 2023 Global Climbing Team:

We also extend our sincerest appreciation to the climbers taking on the physical and mental challenge of climbing to Annapurna Base Camp, all in the name of raising funds for the iCMLf. Your determination, resilience, and unwavering support are an inspiration.

Support our climbers and CML Patients 2

You can donate to the individual climbers here.

Please support our Climb for a Cure

All donations, whether big or small, make a difference and reaffirm our collective commitment to finding a cure for CML.

From the bottom of our hearts, thank you for climbing with us on this journey.

Donate to the Climb For a Cure Annapurna 2023

If you are interested in climbing with us, you still can – Register here.

Page 1 of 7

Copyright © 2023 All Rights Reserved. The iCMLf is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK